Drug intelligence / Profile preview

OPT-200

Development stage: Preclinical
Lead developer: Oppilotech
Modality: Small Molecules
Administration: Parenteral

Overview

OPT-200 is a preclinical-stage therapeutic candidate being developed by Oppilotech for the treatment of Gram-negative bacterial infections. Discovered through Oppilotech's proprietary systems biology and computational modeling platform, the drug is designed to target lipopolysaccharide (LPS), a fundamental component of the outer membrane of Gram-negative bacteria. LPS is essential for bacterial viability, structural integrity, and protection against environmental stressors, including antibiotics. By disrupting LPS biosynthesis or transport, OPT-200 aims to provide a novel mechanism for combating multi-drug resistant (MDR) pathogens, which represent a significant unmet medical need in infectious disease.

Other names: OPT-200OPT200OPT 200

Targets

LpxC (UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase)

Beyond the preview

Go deeper on OPT-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPT-200.

Explore the full profile